Welcome to our dedicated page for Zura Bio SEC filings (Ticker: ZURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zura Bio Limited (Nasdaq: ZURA) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage, multi-asset immunology company developing novel antibodies for autoimmune and inflammatory diseases, Zura Bio uses its SEC filings to report on financial performance, risk factors, governance matters, and material corporate events.
Through periodic reports such as the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, Zura Bio presents audited and unaudited financial statements, details on research and development expenses, general and administrative costs, cash and cash equivalents, and net losses. These filings also describe the company’s pipeline, including tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880), and outline key risks associated with its clinical-stage status and lack of approved products.
Current reports on Form 8-K document specific material events, such as leadership transitions, executive appointments, adoption of executive severance plans, financial result announcements, and updates to corporate presentations. For example, Zura Bio has filed 8-Ks regarding changes in its chief executive officer and chief financial officer roles, the launch of investor presentations, and the release of quarterly financial results.
On Stock Titan, these filings are supplemented by AI-powered summaries that aim to explain the main points of lengthy documents, helping readers quickly identify items such as cash runway disclosures, clinical program descriptions, or changes in executive compensation arrangements. Users can also review exhibits referenced in 8-Ks, including press releases and key agreements, where available.
This page is useful for investors and researchers who want to analyze Zura Bio’s official regulatory record, track how its immunology programs are described in formal filings, and monitor governance and compensation developments over time, all with real-time updates sourced from the SEC’s EDGAR system.
Zura Bio Ltd director Mark Eisner filed an initial Form 3 ownership report. This filing identifies him as a director of Zura Bio Ltd but does not list any stock transactions or share amounts. It serves as a baseline disclosure of his status as an insider for future reporting.
Zura Bio Limited is offering Class A ordinary shares and pre-funded warrants in a primary registered offering (preliminary prospectus supplement dated
The company’s Class A ordinary shares trade on Nasdaq under “ZURA”; the last reported sale price on February 23, 2026 was $6.53. The prospectus discloses a preliminary cash and cash equivalents estimate of $109.4 million as of December 31, 2025 (unaudited). The share count basis used is 65,018,058 Class A ordinary shares outstanding as of September 30, 2025.
Proceeds are intended for working capital, advancing the pipeline and general corporate purposes. The offering is subject to completion of terms, underwriting arrangements, and customary conditions; information on offering size, price per share and aggregate proceeds is omitted in the provided excerpt.
Zura Bio Limited reported board changes and new director compensation terms. Neil Graham resigned from the board of directors on February 21, 2026, and the company states his resignation was not due to any disagreement with management, strategy, or operations.
On the same date, the board appointed two experienced immunology and drug development leaders, Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., as directors. Each will receive a prorated annual cash retainer of $40,000 and an initial stock option grant to purchase the lesser of 51,000 Class A ordinary shares or the number with an option value capped at $200,000, vesting over one year. They will also be eligible for similarly structured annual option grants for continued service. A press release with additional background on the new directors and Zura’s clinical-stage pipeline, including Phase 2 studies of tibulizumab (ZB-106) in hidradenitis suppurativa and systemic sclerosis, was furnished as an exhibit.
Great Point Partners, LLC and two affiliated individuals report a significant stake in Zura Bio Ltd. They beneficially own 3,815,930 Class A Ordinary Shares, representing 5.18% of the class, as of an event date of December 31, 2025.
The ownership is held through Biomedical Value Fund, L.P. with 2,632,991 shares and Biomedical Offshore Value Fund, Ltd. with 1,182,939 shares. Zura Bio had 73,680,710 shares outstanding as of December 31, 2025. The filers certify the holdings are passive and not for influencing control.
Suvretta Capital Management and related investors have filed an amended Schedule 13G reporting significant passive ownership in Zura Bio Limited. Suvretta and its principal, Aaron Cowen, each report beneficial ownership of 5,567,001 Class A ordinary shares, representing 8.6% of the class, mainly through advisory clients.
Averill Master Fund, Ltd., an advisory client of Suvretta, reports beneficial ownership of 4,995,444 shares, or 7.7% of the class. Voting and dispositive power over these shares is shared, with no sole voting or dispositive authority reported for any of the three reporting persons.
The securities are held by Suvretta’s advisory clients, and the investors certify that the shares were not acquired and are not held for the purpose of changing or influencing control of Zura Bio, but instead on a passive basis.
Zura Bio Limited furnished an updated corporate presentation dated February 11, 2026 that may be used at upcoming conferences and investor meetings. The full presentation is included as Exhibit 99.1 and can also be accessed via the News & Events section of the company’s investor website.
The company specifies that the material furnished under Item 7.01, including Exhibit 99.1, is provided under Regulation FD, is not considered “filed” for purposes of the Securities Exchange Act or Securities Act liability provisions, and is not automatically incorporated by reference into other SEC filings unless specifically referenced.
Zura Bio Ltd director Parvinder Thiara reported receiving a share option award covering 38,823 Class A Ordinary Shares. The option, with a conversion or exercise price of
The option vests in twelve substantially equal monthly installments over a one-year period starting
Zura Bio Ltd director Parvinder Thiara reported initial derivative holdings in the company. This Form 3 shows two stock option positions over Class A ordinary shares.
The director holds a share option for 48,149 Class A ordinary shares at an exercise price of
Athanor Capital and UGS Capital LLC filed a Schedule 13D reporting beneficial ownership of 11,581,402 Class A Ordinary Shares of Zura Bio Limited, representing about 15.7% of the company’s outstanding Class A shares, based on 73,680,710 shares.
On December 29, 2025, Zura Bio issued Athanor Capital 8,657,402 Class A shares under a letter agreement, with no cash paid; the shares were issued in exchange for terminating prior agreements and transferring certain contractual rights. The investors state the stake is held for investment purposes, without a present intent to change or influence control, though they may review the position over time. Parvinder Thiara, associated with both entities, was reappointed to Zura Bio’s board effective January 23, 2026.
Zura Bio Limited announced a leadership transition. Robert Lisicki resigned as Chief Executive Officer, principal executive officer and director, effective January 21, 2026, after previously taking medical leave. Under a separation agreement, he will remain a non-executive employee through March 31, 2026 with transition pay of $72,000 on an annualized basis, a lump-sum severance equal to 12 months of base salary reduced by that transition pay, COBRA premiums for up to nine months, an extended 12‑month post-termination option exercise window, and accelerated vesting for 25% of the stock options granted to him on February 27, 2025.
The Board appointed director Dr. Sandeep Kulkarni as Chief Executive Officer and principal executive officer, with an annual base salary of $655,000 and a target bonus equal to 55% of base salary, and equity awards under the 2023 Equity Incentive Plan. Kim Davis stepped down from interim CEO duties and continues as Chief Operating Officer, Chief Legal Officer and Corporate Secretary. The Board also appointed Parvinder Thiara as a director, with a prorated $40,000 annual cash retainer and stock option grants tied to service under the Non-Employee Director Compensation Policy.